Embecta (NASDAQ:EMBC) Releases FY 2024 Earnings Guidance

Embecta (NASDAQ:EMBC) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 2.300-2.350 for the period, compared to the consensus estimate of 2.280. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Embecta also updated its FY24 guidance to $2.30-2.35 EPS.

Embecta Stock Performance

Shares of NASDAQ EMBC opened at $15.39 on Monday. The firm’s 50 day moving average price is $13.35 and its 200-day moving average price is $13.35. Embecta has a 52-week low of $9.93 and a 52-week high of $22.16. The company has a market cap of $887.54 million, a PE ratio of 12.72 and a beta of 0.99.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Friday, August 9th. The company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.26. The firm had revenue of $272.50 million for the quarter, compared to analysts’ expectations of $267.44 million. Embecta had a net margin of 6.20% and a negative return on equity of 18.42%. The business’s quarterly revenue was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.69 EPS. On average, analysts forecast that Embecta will post 2.29 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Stockholders of record on Tuesday, August 27th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 3.90%. The ex-dividend date is Tuesday, August 27th. Embecta’s payout ratio is 49.59%.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley decreased their target price on Embecta from $13.00 to $12.00 and set an underweight rating on the stock in a report on Monday, July 15th.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.